Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia
Adding a weekly shot to a daily leukemia pill boosts deep remission rates
This phase 3 trial compared nilotinib monotherapy against nilotinib combined with pegylated interferon alfa-2a in patients with newly diagno…
A weekly injection added to a daily pill helped more newly diagnosed CML patients reach deep remission, but it also caused more side effects…
Preoperative indicators predict microvascular invasion in hepatocellular carcinoma patients
New Model Predicts Liver Cancer Spread Before Surgery
This meta-analysis evaluated preoperative indicators including alpha-fetoprotein, tumor size, and tumor margin to predict microvascular inva…
A simple scoring tool now predicts if liver cancer has spread into tiny blood vessels, helping surgeons plan safer operations and improve su…
Meta-analysis of surgical resection for lung neuroendocrine tumors
Sparing Lung Tissue May Save Lives Without Hurting Survival Rates
This meta-analysis of six studies compared lobectomy to sub-lobar resection for lung neuroendocrine tumors. It found no significant differen…
New research shows taking less lung tissue during surgery for rare tumors gives patients the same long-term survival chance as taking more.
Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
Gemcitabine and docetaxel show similar recurrence-free survival to BCG for bladder cancer
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Guérin (BCG) in pa…
A meta-analysis of 1634 patients found gemcitabine and docetaxel offered recurrence-free survival rates comparable to BCG therapy for non-mu…
Narrative review suggests phytochemicals and phages may augment conventional antibiotics for brucellosis
New plant-based and phage options might help treat stubborn brucellosis infections in people and animals
This narrative review discusses novel strategies for treating brucellosis in humans and animals. The authors note that conventional antibiot…
Standard antibiotics sometimes fail to cure brucellosis, and bacteria are becoming resistant. New methods using plant chemicals and viruses …
Scoping review links housing insecurity and indoor pollutants to increased cancer risk and reduced survival
Your Home Safety Could Be The Key To Lowering Cancer Risk Today
This scoping review examines populations exposed to housing and energy insecurity, including women and low-income households. The authors sy…
Living in unsafe homes with poor air quality and energy poverty makes cancer more likely and harder to beat for many people.
Meta-analysis identifies genetic variants linked to HBV susceptibility and HCC risk
Genetic Keys Unlock Why Some Get Liver Cancer From Hepatitis B
This meta-analysis of East Asian cohorts examined genetic variants associated with hepatitis B virus infection and hepatocellular carcinoma …
New research shows specific gene changes help explain why some people get Hepatitis B while others stay healthy.
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.